Britain's Dieting Shift

Nearly half of UK adults are now following a specific diet, and British restaurants are being pushed to add more protein, lighter dishes and smaller portions. (circana.com) Circana said on April 20 that 45% of British adults are following a specific diet, rising to 60% among Gen Z and younger millennials. The same report said 23% of consumers looking for higher-protein, lower-calorie meals will switch venues if they do not find those options. (circana.com) The market researcher said demand is moving toward energy, immunity and weight-management products, while operators are being nudged toward protein-forward menus, lower-sugar items and portion-controlled servings. Retail Times, which republished the findings, said GLP-1 awareness in Britain rose from 69% in May 2025 to 75% in January 2026. (circana.com) (retailtimes.co.uk) GLP-1 drugs are medicines that mimic a gut hormone tied to appetite and blood sugar. In Britain, semaglutide is recommended by the National Institute for Health and Care Excellence for weight management only alongside diet and exercise, within specialist services, and generally for adults with obesity plus at least one weight-related condition. (nice.org.uk) That matters for restaurants because the drugs can change what people order, not just whether they go out. Circana’s U.S. research published in January found GLP-1 users were cutting back on alcohol and retail food purchases even as restaurant spending held up, with casual dining showing the biggest increase. (nrn.com) (foodinstitute.com) Britain’s rollout is still more constrained than the social-media buzz suggests. Government guidance says GLP-1 medicines are not approved for cosmetic or quick weight loss, and National Health Service access has been limited by eligibility rules and specialist-service capacity. (gov.uk) (nice.org.uk) Even so, access is widening. The Medicines and Healthcare products Regulatory Agency approved a new single-dose 7.2 milligram Wegovy pen on April 14, 2026, and NHS England said on April 1 that up to 1.2 million people with cardiovascular disease could become eligible for semaglutide over the next few years to reduce heart attack and stroke risk. (gov.uk) (england.nhs.uk) Circana’s read is that the menu shift is already arriving before mass drug uptake does. In Britain’s dining market, younger customers asking for more protein and fewer calories are shaping the offer first, and GLP-1 awareness is adding pressure behind them. (circana.com)